EUCTR2017-002605-35-BE进行中（未招募）1 期
A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma.
HOVON Foundation0 个研究点目标入组 109 人开始时间: 2018年8月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 109
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age 18-75 (inclusive) years
- •Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma (DLBCL-NOS) based upon a representative histology specimen according to the WHO classification, revision 2016
- •Ann Arbor stages II-IV
- •WHO performance status 0 – 1
- •IPI >=3 at diagnosis
- •Complete metabolic remission (Deauville 1-3) after 6-8 cycles of R-CHOP according to the Lugano criteria
- •Negative pregnancy test at study entry
- •Patient is willing and able use adequate contraception during and until 6 months after the last protocol treatment.
- •Written informed consent
- •Patient is capable of giving a written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 67
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 42
排除标准
- •All histopathological diagnoses other than DLBCL-NOS according to the WHO classification, revision 2016,including:
- •-High-grade B-cell lymphoma with a double/triple translocation with MYC, BCL2 and/or BCL6. Please note that patients with an isolated MYC
- •translocation or an isolated BCL2 translocation or an isolated BCL-6 translocation are eligible (single hit translocation).
- •-Testicular large B-cell lymphoma
- •-Primary mediastinal B cell lymphoma
- •-Transformed indolent lymphoma
- •-Post-transplant lymphoproliferative disorder
- •Organ dysfunction
- •Clinical signs of severe pulmonary dysfunction.
- •Clinical signs of heart failure (NYHA classification II-IV).
- •Symptomatic coronary artery disease or cardiac arrhythmias not well controlled with medication.
- •Myocardial infarction during the last 6 months.
- •Significant renal dysfunction (serum creatinine = 150 umol/l or clearance = 30ml/min
- •Creatinine clearance may be calculated by Cockcroft –Gault formula.
- •Inadequate hematological function: hemoglobin < 5.5 mmol/L , ANC < 1.0x109/L or platelets < 75x109 /L
- •Signs or known history of bleeding disorder
- •Spontaneous INR > 1.5, aPTT >33
- •Significant hepatic dysfunction (total bilirubin = 1.5x upper limit of normal (ULN) or transaminases = 2.5 x ULN), unless related to Gilberts syndrome.
- •Clinical signs of severe cerebral dysfunction
- •Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
- •Major surgery within the last 4 weeks
- •Known or suspected infection
- •Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 before date of registration. Suspected active or latent tuberculosis needs to be confirmed by positive interferon gamma (IFN-?) release assay
- •Patients known to be HIV-positive
- •Active chronic hepatitis B or C infection
- •Administration of a live, attenuated vaccine within 4 weeks before date of registration or anticipation that such a live attenuated vaccine will be required during the study and for a period of 5 months after discontinuation of atezolizumab.
- •Auto-immune
- •Any active or history of documented autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
- •The following exceptions are allowed: Patients with autoimmune-related hypothyroidism or type 1 diabetes mellitus who are on stable treatment.
- •History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest CT scan at screening.
- •Patients with uncontrolled asthma or allergy, requiring systemic steroid treatment
- •Regular treatment with corticosteroids within the 4 weeks prior to date of registration, unless administered for indications other than NHL at a dose equivalent to < 30 mg/day prednison
研究者
相似试验
进行中（未招募）
1 期
A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma.EUCTR2017-002605-35-NLHOVON Foundation109
招募中
2 期
A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphomaDiffuse large B-cell lymphoma10025320lymphomaNL-OMON52540HOVO90
招募中
1 期
A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCTIS2022-501686-47-00Galapagos25
进行中（未招募）
1 期
A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.EUCTR2021-003815-25-ESCellPoint B.V.45
进行中（未招募）
1 期
A study with the aim to evaluate the antitumor activity of a new association of oral drugs, lenalidomide and clarithromycin in patients with lymphoma (MALT), when standard treatment with radiation therapy, chemotherapy and / or immunotherapy have shown a lack of efficacy.Patients with lymphoid tissue lymphoma mucosa-associated (MALT) for which the standard treatments with radiotherapy, chemotherapy and / or immunotherapy show lack of efficacy.MedDRA version: 21.0Level: PTClassification code 10015823Term: Extranodal marginal zone B-cell lymphoma (MALT type) recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10015824Term: Extranodal marginal zone B-cell lymphoma (MALT type) refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-003168-35-ITIELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP68